Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fsd Pharma Inc Subordinate Voting Share (HUGE.CN)

Fsd Pharma Inc Subordinate Voting Share (HUGE.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 66,583
  • Shares Outstanding, K 30,969
  • Annual Sales, $ 257 K
  • Annual Income, $ -52,013 K
  • 60-Month Beta N/A
  • Price/Sales 76.62
  • Price/Cash Flow N/A
  • Price/Book 1.56
Trade HUGE.CN with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.850 +18.92%
on 03/05/21
5.240 -58.02%
on 02/11/21
-0.750 (-25.42%)
since 02/08/21
3-Month
1.850 +18.92%
on 03/05/21
5.240 -58.02%
on 02/11/21
-0.160 (-6.78%)
since 12/08/20
52-Week
1.700 +29.41%
on 11/13/20
14.740 -85.07%
on 06/03/20
-3.950 (-64.23%)
since 03/06/20

Most Recent Stories

More News
Court Orders FSD Pharma to Move Shareholder Meeting Date to May 14, 2021, Imposes Requirement of an Independent Meeting Chair and Prevents Dr. Raza Bokhari and Other Directors from Voting Recently Issued Shares

, /PRNewswire/ - The group of concerned shareholders (the "") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (the "" or "") which includes two founding directors, and , are pleased to announce...

HUGE : 1.7400 (+2.96%)
HUGE.CN : 2.210 (+5.24%)
FSD Pharma Announces US$20M At-The-Market Offering

FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that it has entered into an Equity Distribution Agreement dated February 11, 2021 (the "Sales Agreement") with A.G.P./Alliance...

HUGE : 1.7400 (+2.96%)
HUGE.CN : 2.210 (+5.24%)
FSD Provides Corporate Update

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) ("FSD Pharma" or the "Company") today announces the following corporate updates.

HUGE : 1.7400 (+2.96%)
HUGE.CN : 2.210 (+5.24%)
FSD Pharma Sets Date for Annual Meeting

FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that it will hold its annual meeting of shareholders (the "Meeting") on June 29, 2021.

HUGE : 1.7400 (+2.96%)
HUGE.CN : 2.210 (+5.24%)
FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) ("FSD Pharma" or the "Company") today announced the dosing of the first patient in its Phase 2a clinical trial of FSD201 (ultramicronized palmitoylethanolamide,...

HUGE : 1.7400 (+2.96%)
HUGE.CN : 2.210 (+5.24%)
FSD Pharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) ("FSD Pharma" or the "Company") today announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update. The filing...

HUGE : 1.7400 (+2.96%)
HUGE.CN : 2.210 (+5.24%)
FSD Pharma Announces Settlement of Class Action Proceeding

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that, subject to court certification and other customary conditions, it has entered into a definitive settlement...

HUGE : 1.7400 (+2.96%)
HUGE.CN : 2.210 (+5.24%)
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients

- FDA has authorized randomized, controlled, double-blind, multicenter study on 352 patients

HUGE.CN : 2.210 (+5.24%)
HUGE : 1.7400 (+2.96%)
FSD Pharma Announces Phase 2 Clinical Trial IND Filing with the FDA to Treat Patients with COVID-19

- The study is expected to be conducted at 25-30 hospitals in North America -

HUGE.CN : 2.210 (+5.24%)
HUGE : 1.7400 (+2.96%)
FSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip Video

Vancouver, British Columbia--(Newsfile Corp. - July 31, 2020) - CEO and Chairman, Raza Bokhari speaks about the company's lead Compound, PEA, to treat COVID-19.

HUGE.CN : 2.210 (+5.24%)
HUGE : 1.7400 (+2.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 2.633
2nd Resistance Point 2.427
1st Resistance Point 2.263
Last Price 2.210
1st Support Level 1.893
2nd Support Level 1.687
3rd Support Level 1.523

See More

52-Week High 14.740
Fibonacci 61.8% 9.759
Fibonacci 50% 8.220
Fibonacci 38.2% 6.681
Last Price 2.210
52-Week Low 1.700

See More

Business Summary

FSD Pharma Inc is a publicly traded company, through its wholly-owned subsidiary holds an Access to Cannabis for Medical Purposes Regulation license to cultivate cannabis. It is engaged in the production and sale of medical cannabis. All of the company's operations are situated in Canada.

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar